The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
oxford has been extending their subject recruitment today,
actively inviting additional participation from a number of
NHS organisations in particular ... they are looking to recruit
more 18-55 front-line workers, who may be at higher exposure risk.
(i should have said before, the ‘placebo’ /control is itself a vaccine,
but a known and well tested vaccine against adolescent meningitis
and sepsis, usually with very few safety problems, but where there
is no good reason at all to think it would protect against covid19).
Yes your right spikeyj, I don’t think they will run out of volunteers though. What I don’t understand is how there can be different vaccines from different companies for covid 19. Assuming some come through. I Dont understand the science behind it.
Let’s hope someone comes up with a vaccine as South Korea having recently opened up schools have had to close again due to outbreak.
Still I suppose we will get local outbreaks for the foreseeable future.
seaking, issue is not about them doing the study in an unusual way, just
about whether the study has adequate sample size /sufficiently powered.
for sure, the trial is still under way, and has not been
abandoned, so yes, let’s all hope that it does bear fruit.
That’s the way it’s always done.
Disagree with what’s been put out by the media. The imminent results of the first trial by AstraZeneca/ Jenner / Oxford uni, will be put out as an Rns tomorrow or maybe over the weekend.
Let’s All hope it’s good.
oxford uni has been caught out by how quickly this first wave
of covid19 has died down in the UK. if they had anticipated,
then they could have adjusted by recruiting bigger sample size.
countries will vary in the prevalence rates of virus in the community.
currently, a pharma company based in brazil or russia would have a
better chance of getting its subjects infected than one based in the UK.
( it would be different of course if pharma companies were allowed
to deliberately infect their human subjects in order to test the vaccine.)
hi retiredcopper.
issue for the oxford uni people, they’ve given half their test subjects
a placebo, and half their test subjects a (candidate) vaccine - now they
need to wait & see if the half of their subjects that got the real vaccine
do any better (or worse) than the ones with placebo. but if very very
few of the subjects get exposed to the virus while they go about their
daily lives, then very few of them will get ill anyway, and statistically
they probably wouldn’t be able to tell if there is a significant difference
between the ones with placebo vs ones with the candidate vaccine.
for the statistics to work, they need a fair few
to encounter the virus in the community.
https://pharmaphorum.com/news/gsk-to-produce-a-billion-doses-of-covid-19-vaccine-booster-by-2021/
GlaxoSmithKline is to scale up production of its COVID-19 vaccine booster to a billion doses by 2021 to support development of several potential jabs.
Adjuvants, which boost the immune response caused by a vaccine, could be important should one of the many potential vaccines against the SARS-CoV-2 virus make it through clinical trials.
Demand for any successful vaccine will be immense and in order to meet global demands it will be important to use small amounts of vaccine protein to ensure there is enough to go round.
Adjuvants can also enhance the immune response and have been shown to create a stronger and longer-lasting immunity against infections.
Sanofi has partnered with several different pharmas and biotechs producing potential vaccines against COVID-19.
These include France’s Sanofi and China’s Xiamen Innovex, after CEO Emma Walmsley pledged to make the adjuvant technology available at a summit at the White House involving the world’s pharma leaders and president Donald Trump at the beginning of March.
Confirmation of the enhanced manufacturing capacity follows completion of a review conducted across the company’s global supply network. GSK will manufacture, fill and finish the adjuvant for use in COVID-19 vaccines at sites in the UK, US, Canada and Europe.
GSK has decided to scale up manufacturing of the adjuvant at risk as there are no vaccines approved to treat COVID-19.
It is in talks with governments and global institutions about funding for production and supply of the adjuvant.
The company says it does not expect to profit from sales of its portfolio of collaborations for COVID-19 vaccines during the pandemic phase of the COVID-19 outbreak.
Profit generated will be invested in support of coronavirus related research and long-term pandemic preparedness, either through GSK’s internal investments, or with external partners.
It added that it is committed to making the adjuvant available to people across the world. This could include donations to the world’s poorest countries, and will work with governments and institutions to prioritise access.
According to a regularly-updated document maintained by the World Health Organization, there are 10 vaccines in clinical trials for COVID-19, and 115 in preclinical development.